News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

Can-Fite BioPharma Ltd. (NYSE American: CANF) today announced that its study titled “Allosteric A3 Adenosine Receptor CF602 Modulator Reverses Erectile Dysfunction in a Diabetic Rat Model” has been published in the peer-reviewed journal Andrology.

Full erectile recovery was achieved after a single dose of CF602 with restored muscle collagen ratio and endothelial cell function. Can-Fite’s CF602, an allosteric modulator of the A3 adenosine receptor (A3AR), applied topically or orally in a diabetic rat model, resulted in increased arterial blood flow and significant improvements as a function of intracavernous pressure (ICM) dose, smooth muscle: collagen ratio, vascular endothelial growth factor, and endothelial nitric oxide synthase.

While oral phosphodiesterase type 5 (PDE5) inhibitors are the current standard of care for erectile dysfunction (ED), with brands such as Viagra, Cialis, Levitra and Stendra estimated 30% to 35% of emergency department patients are unresponsive, and these drugs may be contraindicated for people with diabetes.

The data published in the article suggests that CF602 could potentially offer an alternative treatment to PDE5 inhibitors, especially for PDE5 non-responders and diabetics.

“There is a clear and unmet need on the market today for an effective alternative to PDE5 inhibitors for non-responders to major sexual dysfunction drugs and diabetics, many of whom cannot be prescribed in safety of PDE5 inhibitors. With a growing body of data and intellectual property surrounding CF602, we are evaluating potential strategic partnerships to advance CF602 to market,” said Can-Fite CEO Dr. Pnina Fishman.

According to Zion Market Research, the global ED market was valued at $3.64 billion in 2021 and is expected to reach $5.94 billion by 2028.